文献速递神经肿瘤

脑膜瘤与醋酸环丙孕酮:388例手术或放疗患者的单中心回顾性队列

Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
PubMed 文献 · J Neurooncol · 2021-01-03

该单中心回顾性研究纳入2014至2017年因颅内脑膜瘤接受手术或放疗的388例患者,其中3.9%有醋酸环丙孕酮(CPA)使用史或正在使用。与无激素暴露组相比,CPA暴露组脑膜瘤发病年龄更早(48.9岁 vs 61.9岁,p=0.0005),多发脑膜瘤比例更高(26.7% vs 6.1%,p=0.0115)。

要点

  • CPA暴露者脑膜瘤发病年龄明显提前,平均48.9岁 vs 61.9岁。
  • CPA暴露者多发脑膜瘤比例更高,26.7% vs 6.1%。
  • 本队列CPA暴露比例为3.9%,其他激素治疗占16.2%。

核心结论

  • 有CPA使用史或正在使用的患者脑膜瘤数量更多,且发病年龄显著更年轻。

研究设计与样本

  • 单中心回顾性研究,纳入2014至2017年因颅内脑膜瘤接受手术或放疗的患者。
  • 共纳入388例,其中277例接受手术,111例接受放疗。
  • 排除有电离辐射暴露史或2型神经纤维瘤病者。

主要发现

  • 3.9%的患者有CPA使用史或正在使用,16.2%使用其他激素治疗。
  • CPA暴露组发病年龄48.9岁,无激素暴露组61.9岁(p=0.0005)。
  • CPA暴露组多发脑膜瘤占26.7%,无激素暴露组占6.1%(p=0.0115)。

关键数值与推荐

  • CPA暴露定义为有CPA使用史或当前使用。
  • 比较对象为无激素暴露组及暴露于其他激素的患者。

临床怎么用

  • 对颅内脑膜瘤患者应询问CPA等激素使用史,尤其年轻及多发脑膜瘤患者。

局限性

  • 单中心回顾性设计,样本来自南特地区,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Meningiomas are the most common intracranial tumors, accounting for 20-30% of central nervous system tumors. Recently, the European Medicines Agency issued an alert on cyproterone acetate (CPA) based on the results of a study that found an increased risk of meningioma 7 to 20 times higher when a patient is on CPA. The primary objective of this study was to determine the prevalence of CPA exposure in patients who had one or more intracranial meningiomas treated surgically or with radiation therapy. The secondary objectives were to establish a description of the patients who had intracranial meningioma in Nantes and to establish whether there was a difference in the intrinsic and tumoral characteristics of patients exposed to CPA compared with patients who had no hormonal exposure and patients who had been exposed to other hormones. METHODS: Monocentric, retrospective study including all patients treated by surgery or radiotherapy for intracranial meningioma from 2014 to 2017 excluding those with a history of exposure to ionizing radiation or neurofibromatosis type 2. RESULTS: 388 patients were included, 277 were treated by surgery and 111 by radiotherapy. 3.9% of the patients had a history or current use of CPA, 16.2% were taking other hormonal treatment. Compared with the group without hormonal exposure, the CPA-exposed group had significantly an earlier onset of meningiomas at 48.9 vs. 61.9 years (p = 0.0005) and had more multiple meningiomas, 26.7% vs. 6.1% (p = 0.0115). CONCLUSIONS: In our study, patients with a history or current use of CPA had significantly more meningiomas and were significantly younger at the onset.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Samarut E, Lugat A, Amelot A, et al. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma. J Neurooncol. 2021. PMID: 33392938. doi:10.1007/s11060-020-03683-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。